186 related articles for article (PubMed ID: 26584836)
1. Thermal stability of self-assembled peptide vaccine materials.
Sun T; Han H; Hudalla GA; Wen Y; Pompano RR; Collier JH
Acta Biomater; 2016 Jan; 30():62-71. PubMed ID: 26584836
[TBL] [Abstract][Full Text] [Related]
2. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
[TBL] [Abstract][Full Text] [Related]
3. Peptides-Based Vaccine MP3RT Induced Protective Immunity Against
Gong W; Liang Y; Mi J; Jia Z; Xue Y; Wang J; Wang L; Zhou Y; Sun S; Wu X
Front Immunol; 2021; 12():666290. PubMed ID: 33981313
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes.
Wu Y; Kelly SH; Sanchez-Perez L; Sampson JH; Collier JH
Biomater Sci; 2020 Jun; 8(12):3522-3535. PubMed ID: 32452474
[TBL] [Abstract][Full Text] [Related]
5. Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope.
Rudra JS; Mishra S; Chong AS; Mitchell RA; Nardin EH; Nussenzweig V; Collier JH
Biomaterials; 2012 Sep; 33(27):6476-84. PubMed ID: 22695068
[TBL] [Abstract][Full Text] [Related]
6.
Clemmensen HS; Dube JY; McIntosh F; Rosenkrands I; Jungersen G; Aagaard C; Andersen P; Behr MA; Mortensen R
mBio; 2021 Apr; 12(2):. PubMed ID: 33879592
[TBL] [Abstract][Full Text] [Related]
7. The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation.
Chen J; Pompano RR; Santiago FW; Maillat L; Sciammas R; Sun T; Han H; Topham DJ; Chong AS; Collier JH
Biomaterials; 2013 Nov; 34(34):8776-85. PubMed ID: 23953841
[TBL] [Abstract][Full Text] [Related]
8. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.
Bennekov T; Dietrich J; Rosenkrands I; Stryhn A; Doherty TM; Andersen P
Eur J Immunol; 2006 Dec; 36(12):3346-55. PubMed ID: 17109467
[TBL] [Abstract][Full Text] [Related]
9. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant.
Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of late stage specific peptide antigens of Mycobacterium tuberculosis.
Singh M; Bhatt P; Sharma M; Varma-Basil M; Chaudhry A; Sharma S
Infect Genet Evol; 2019 Oct; 74():103930. PubMed ID: 31228643
[TBL] [Abstract][Full Text] [Related]
11. Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development.
Mohammed AR; Bramwell VW; Kirby DJ; McNeil SE; Perrie Y
Eur J Pharm Biopharm; 2010 Nov; 76(3):404-12. PubMed ID: 20884349
[TBL] [Abstract][Full Text] [Related]
12. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice.
McMurry JA; Kimball S; Lee JH; Rivera D; Martin W; Weiner DB; Kutzler M; Sherman DR; Kornfeld H; De Groot AS
Curr Mol Med; 2007 Jun; 7(4):351-68. PubMed ID: 17584075
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Potential of Poly-α-l-Glutamine from the Cell Wall of Mycobacterium tuberculosis.
Mani R; Gupta M; Malik A; Tandon R; Prasad R; Bhatnagar R; Banerjee N
Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30104212
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of T-cell responses to peptides with MHC class I-binding motifs derived from PE_PGRS 33 protein of Mycobacterium tuberculosis.
Chaitra MG; Shaila MS; Nayak R
J Med Microbiol; 2007 Apr; 56(Pt 4):466-474. PubMed ID: 17374885
[TBL] [Abstract][Full Text] [Related]
15. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.
Thakur A; Ingvarsson PT; Schmidt ST; Rose F; Andersen P; Christensen D; Foged C
Vaccine; 2018 May; 36(23):3331-3339. PubMed ID: 29699790
[TBL] [Abstract][Full Text] [Related]
16. Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8
Si Y; Wen Y; Kelly SH; Chong AS; Collier JH
J Control Release; 2018 Jul; 282():120-130. PubMed ID: 29673645
[TBL] [Abstract][Full Text] [Related]
17. Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers.
Mora-Solano C; Wen Y; Han H; Chen J; Chong AS; Miller ML; Pompano RR; Collier JH
Biomaterials; 2017 Dec; 149():1-11. PubMed ID: 28982051
[TBL] [Abstract][Full Text] [Related]
18. New alternative vaccine component against mycobacterium tuberculosis--heat shock protein 16.3 or its T-cell epitope.
Shi C; Zhang H; Zhang T; Wang X; Bai B; Zhao Y; Zhang C; Xu Z
Scand J Immunol; 2009 Nov; 70(5):465-74. PubMed ID: 19874551
[TBL] [Abstract][Full Text] [Related]
19. Active immunotherapy for C5a-mediated inflammation using adjuvant-free self-assembled peptide nanofibers.
Hainline KM; Haddad HF; Gilpin A; Curvino EJ; Varghese S; Collier JH
Acta Biomater; 2024 Apr; 179():83-94. PubMed ID: 38447809
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
